Physician profile
Mohammed Barawi
NPI 1972584191
$193,477.72
in general payments reported to CMS, 2019-2025
50 companies · $39K in 2025
The $39K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $17K · 2021: $22K · 2022: $31K · 2023: $17K · 2024: $23K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Food and Beverage: $12K · Travel and Lodging: $9,049 · Consulting Fee: $3,392 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,566.00 |
| Food and Beverage | $11,832.15 |
| Travel and Lodging | $9,049.15 |
| Consulting Fee | $3,392.00 |
| Education | $191.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $93,525.98 | 2019-2025 | Epclusa, Livdelzi |
| Abbvie INC. | $42,682.17 | 2019-2025 | Creon, Rinvoq, Skyrizi |
| Amgen INC. | $15,822.32 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Redhill Biopharma INC. | $8,007.57 | 2020-2023 | Aemcolo, Movantik, Talicia |
| Boston Scientific Corporation | $6,579.59 | 2019-2025 | Spyglass, Axios, General - Metal Stents - G.I. |
| Medtronic, INC. | $6,357.47 | 2021-2025 | Gi Genius, Endoflip |
| Olympus America INC. | $5,144.56 | 2019-2020 | |
| Genzyme Corporation | $3,485.11 | 2022-2025 | |
| Olympus Corporation | $2,095.00 | 2019-2025 | Single Use Electrosurgical Snare Sd-400 |
| Janssen Biotech, INC. | $1,561.91 | 2019-2025 | Tremfya, Stelara |
| Olympus Corporation of The Americas | $1,030.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $738.14 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Apollo Endosurgery US INC | $571.65 | 2019-2023 | Overstitch Endoscopic Suturing System |
| Cook Medical LLC | $541.99 | 2019-2025 | Fusion, Cook Celect |
| Pfizer INC. | $417.56 | 2019-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $414.08 | 2019-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $406.23 | 2019-2025 | Tremfya, Stelara |
| Novo Nordisk INC | $396.00 | 2021-2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $367.31 | 2023-2025 | Terlivaz |
| Erbe USA INC | $340.00 | 2023-2025 | Vio3, Vio3 Apc, Erbe Vio3 |
| Pentax of America, INC. | $306.76 | 2021-2023 | Inspira |
| Celgene Corporation | $267.31 | 2022-2024 | Zeposia, Zerit |
| Madrigal Pharmaceuticals | $253.81 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $241.74 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.71 | 2019-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $200.71 | 2019 | |
| Allergan, INC. | $192.19 | 2019-2020 | |
| Ardelyx, INC. | $183.61 | 2023-2025 | Ibsrela |
| Recor Medical INC | $125.00 | 2024 | Paradise Renal Denervation System |
| Phathom Pharmaceuticals, INC. | $123.50 | 2024 | Voquezna |
| Fisher & Paykel Healthcare INC | $112.59 | 2023-2025 | Fisher & Paykel Healthcare |
| Lilly USA, LLC | $82.51 | 2024-2025 | Omvoh |
| Romark Laboratories, Lc | $80.36 | 2019 | |
| Daiichi Sankyo INC. | $70.64 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $57.54 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $56.60 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $53.35 | 2022-2023 | Rebyota |
| Creo Medical INC. | $50.33 | 2021 | |
| Ambu INC. | $44.51 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $40.30 | 2024-2025 | Dupixent |
| Shionogi INC | $39.04 | 2019 | |
| Concordia Pharmaceuticals INC. | $35.46 | 2019 | |
| Nestle Healthcare Nutrition INC. | $24.15 | 2021 | |
| Vivus LLC | $18.39 | 2024 | Qsymia |
| W. L. Gore & Associates, INC. | $18.21 | 2023 | Gore Cardioform Septal Occluder |
| Organon LLC | $16.89 | 2023 | Hadlima, Renflexis |
| Aimmune Therapeutics, INC. | $15.74 | 2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $15.22 | 2023 | Ocaliva |
| Braintree Laboratories, INC. | $14.01 | 2019 | |
| Ucb, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Barawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.